Announced expected recognition of inventory valuation loss of 46 million yen and impairment loss on fixed assets of 11 million yen. These are within the scope of the earnings guidance, and no revision to the guidance will be made at this time.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4880","jir_company_name":"CellSource Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4880-20261013-01.pdf","jir_short_summary":"Announced expected recognition of inventory valuation loss of 46 million yen and impairment loss on fixed assets of 11 million yen. These are within the scope of the earnings guidance, and no revision to the guidance will be made at this time.","jir_summary":"### Key Points of the News\nThe Company announced that for the fiscal year ending October 2026, it expects to record an inventory valuation loss of 46 million yen related to the Consumer Business and an impairment loss on fixed assets of 11 million yen. The total impact is assumed to be 58 million yen, and the current earnings guidance remains unchanged.\n\n### Future Actions and Impact\nIf the above losses become additional disclosure items, the Company will promptly disclose them. At present, the Company states that developments are within the scope of the earnings guidance announced on September 8, 2026, and no short-term revisions to the guidance will be made.","jir_financial_highlights":"Expected recognition of inventory valuation loss: 46 million yen (Unknown)\nExpected recognition of extraordinary loss (impairment loss): 11 million yen (Unknown)\nTotal impact amount: 58 million yen (Unknown)","jir_category":"","jir_hashtags":"#CellSource, #DisclosureUpdate","jir_key_figures":"Inventory valuation loss: 46 million yen\nExtraordinary loss (impairment): 11 million yen\nTotal impact amount: 58 million yen","jir_meta_title":"CellSource Co., Ltd. Announces Expected Inventory Valuation Loss and Extraordinary Loss for FY Oct 2026","jir_meta_description":"CellSource Co., Ltd. announced an expected inventory valuation loss of 46 million yen and an extraordinary loss of 11 million yen for the fiscal year ending October 2026. The total impact is 58 million yen, but no revision to the current earnings guidance will be made at this time. Future disclosure plans are also noted.","jir_og_title":"CellSource Co., Ltd. Announces Expected Inventory Valuation and Impairment Losses","jir_og_description":"CellSource Co., Ltd. announced expected recognition of an inventory valuation loss and an impairment loss on fixed assets totaling 58 million yen. The current earnings guidance remains unchanged. Monitor future disclosure responses.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59237,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-129765","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n